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Abstract
AIM: To study the effect of WeiJia on chronic liver injury 
using carbon tetrachloride (CCl4) induced liver injury 
animal model.
METHODS: Wistar rats weighing 180-220g were ran-
domly divided into three groups: normal control group 
(Group A), CCl4 induced liver injury control group (Group 
B) and CCl4 induction with WeiJia treatment group (Group 
C). Each group consisted of 14 rats. Liver damage and 
fibrosis was induced by subcutaneous injection with 40% 
CCl4 in olive oil at 3 mL/kg body weight twice a week for 
eight weeks for Groups B and C rats whereas olive oil 
was used for Group A rats. Starting from the third week, 
Group C rats also received daily intraperitoneal injection 
of WeiJia at a dose of 1.25 µg/kg body weight. Animals 
were sacrificed at the fifth week (4 male, 3 female), and 
eighth week (4 male, 3 female) respectively. Degree of 
fibrosis were measured and serological markers for liver 
fibrosis and function including hyaluronic acid (HA), type 
IV collagen (CIV), γ-glutamyl transferase (γ-GT), alanine 
aminotransferase (ALT) and aspartate aminotransferase 
(AST) were determined. Alpha smooth muscle actin 
(α-SMA) and proliferating cell nuclear antigen (PCNA) 
immunohistochemistry were also performed. 
RESULTS: CCl4 induction led to the damage of liver and 
development of fibrosis in Group B and Group C rats 
when compared to Group A rats. The treatment of WeiJia 
in Group C rats could reduce the fibrosis condition sig-
nificantly compared to Group B rats. The effect could be 
observed after three weeks of treatment and was more 
obvious after eight weeks of treatment. Serum HA, CIV, 
ALT, AST and γ-GT levels after eight weeks of treatment 
for Group C rats were 58±22 µg/L (P<0.01), 57±21 µg/L 
(P<0.01), 47±10 U/L (P<0.01), 139±13 U/L (P<0.05) 
and 52±21 U/L (P>0.05) respectively, similar to normal 
control group (Group A), but significantly different from 
CCl4 induced liver injury control group (Group B). An in-
crease in PCNA and decrease in α-SMA expression level 
was also observed.
CONCLUSION: WeiJia could improve liver function and 
reduce liver fibrosis which might be through the inhibi-
tion of stellate cell activity.
© 2006 The WJG Press. All rights reserved.
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INTRODUCTION
Hepatic fibrosis is one of  the processes that occur when 
the liver is damaged through viral activity, toxins, autoim-
mune diseases, metabolic disorder or genetic defects. It is a 
result of  chronic liver injury that ultimately leads to cirrho-
sis and its complications of  portal hypertension, liver fail-
ure and hepatocellular carcinoma. Millions of  people die 
each year worldwide[1-5]. Efficient and well-tolerated antifi-
brotic drugs are  lacking and current treatment of  hepatic 
fibrosis is limited to withdrawal of  the noxious agent[6]. 
Advance in pathophysiology, molecular biology, ge-
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netically engineered animals, liver transplantation etc. has 
increased our understanding of  the molecular mechanism 
in liver fibrogenesis. Hepatic stellate cell (HSC) was identi-
fied as the primary cell type to mediate fibrogenesis which 
is the major source of  extracellular matrix deposition[7-9]. 
Antifibrotic drug development was focused on fibrogenic 
cells generating the scarring response in the past decade. 
WeiJia is a protein peptide mixture extracted from 
neonate porcine liver. It is a Category-I new drug on the 
market approved by the State Food and Drug Adminis-
tration (SFDA) for the treatment of  severe hepatitis and 
shows promising results in clinical studies[10-12]. Studies also 
showed that WeiJia can act as a therapeutic agent in the 
treatment of  cirrhosis[13, 14]. As progressive hepatic fibrosis 
would lead to cirrhosis, it is likely that WeiJia might also 
play a role in treatment of  hepatic fibrosis. In this study, 
carbon tetrachloride (CCl4) induced liver injury animal 
model was used to evaluate the potential of  WeiJia as a 
therapeutic agent for hepatic fibrosis. 
MATERIALS AND METHODS
Materials
Wistar rats, weighing 180-220g were bought from Experi-
mental Animal Centre, Daping Hospital, Third Military 
Medical University, Chongqing. WeiJia was from LifeTec 
Enterprise Limited, Hong Kong; analytical grade CCl4, 
alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), γ-glutamyl transferase (γ-GT) testing kits and 
DAB were from Sigma (St. Louis, MO, USA); hyaluronic 
acid (HA) and type IV collagen (CIV) RIA kits were from 
Shanghai Naval Medical Research Institute; alpha smooth 
muscle actin (α-SMA) and proliferating cell nuclear anti-
gen (PCNA) monoclonal antibodies were from Dako Ltd. 
(Glostrup, Denmark) 
Animal treatment 
Wistar rats were randomly divided into three groups: nor-
mal control group (Group A), CCl4 induced liver injury 
control group (Group B) and CCl4 induction with WeiJia 
treatment group (Group C). Each group consisted of  14 
rats (8 male, 6 female). Liver damage and fibrosis was in-
duced by subcutaneous injection with 40% CCl4 in olive oil 
at 3 mL/kg body weight twice a week for eight weeks for 
Group B and C rats whereas olive oil alone was used for 
Group A rats. Rats were allowed to feed ad libitum. Start-
ing from the third week, Group C rats also received daily 
intraperitoneal injection of  WeiJia at a dose of  1.25 µg/kg 
body weight. All studies were conducted according to the 
guidelines described in the NIH Guide for the Care and 
Use of  Laboratory Animals. 
Sample collection
Half  of  the rats (4 male, 3 female) in each group were 
sacrificed at the fifth week and the other half  were sacri-
ficed at the eighth week. Amobarbital sodium (0.5%) was 
injected intraperitoneally into the rats at 4 mL/kg and 
blood was collected from the heart after anesthesia. Blood 
(5 mL) was collected and 1.2 mL serum was obtained after 
centrifugation and stored at 4 ℃ before analysis. Liver tis-
sues (1 cm×1 cm×1 cm) from the right liver lobe were dis-
sected and immobilized in 4% paraformaldehyde. Tissue 
was then embedded in paraffin wax and sectioned (4 µm 
thick) before analysis. 
Serum chemistry
Liver fibrosis blood tests for HA and CIV were performed 
using competitive RIA method. Blood serum level of  
γ-GT, ALT and AST were measured by standard clinical 
chemical methods using an automatic analyzer type AL-
CYON 300i (Abbott Laboratories Ltd, USA). 
Histological examination
Tissue was sectioned, haematoxylin and eosin (HE) stain-
ing, Van Gieson (VG) staining and immunohistochemistry 
were performed and examined under light microscope. All 
histological examinations were performed by experienced 
pathologist without prior knowledge of  the animal treat-
ment groups in the study. Images were acquired through 
Nikon Eclipse E400 (Nikon Corporation, Japan) and ana-
lyzed with analySIS 3.0 software. 
Degree of  fibrosis was measured on HE stained sec-
tions. Stage of  liver fibrosis was graded with the META-
VIR scale, which grades fibrosis on a five-point scale: F0 
(no fibrosis), F1 (portal fibrosis without septa), F2 (portal 
fibrosis with a few septa), F3 (numerous septa without cir-
rhosis) and F4 (cirrhosis). METAVIR scale is a widely used 
scale that has excellent inter-observer reliability[15, 16]. 
Ballooning degeneration and steatosis for HE stained 
sections were graded according to a four point scale 
where Grade 0: negative, Grade (1): up to 33%, Grade (2): 
33%-66% and Grade (3): > 66% cells show ballooning de-
generation and steatosis[17].
The collagen content of  the sections was determined 
by VG staining. Five random fields were chosen in each 
section and the amount of  total collagen was detected as 
the area stained by VG and expressed as percentage rela-
tive to the total area. 
α-SMA and PCNA immunohistochemistry were also 
performed. Sections were deparaffinized, rehydrated and 
incubated in 3% hydrogen peroxide at room temperature 
for 10 min to block endogenous peroxidase. After rinsing 
with distilled water, sections were incubated in phosphate 
buffered saline (PBS, 0.01 mol/L, pH 7.4) for 5 min and 
epitope retrieval was induced with heat in a microwave 
oven. Non-specific binding sites were blocked with 10% 
normal goat serum (NGS) / 10% bovine serum albumin (1
∶1 dilution) for 30 min at room temperature followed by 
incubation with monoclonal mouse anti α-SMA or PCNA 
as primary antibodies at 1∶100 dilution in PBS containing 
10% NGS and 0.3% Tween 20 overnight at 4 ℃. Sections 
were then washed with PBS for 3 times, each 5 min before 
applying the secondary antibody. Goat anti-mouse anti-
body conjugated with horseradish peroxidase (HRP) at 1∶
200 dilution in PBS containing 10% NGS was applied and 
the sections were incubated for 30 min at 37 ℃. Sections 
were then washed with PBS for 3 times, each 5 min and 
stained with DAB for 1 to 5 min. Staining was stopped by 
washing with tap water. Sections were counterstained with 
haematoxylin, dried and visualized under light microscope.
Expression of  α-SMA was determined according to 
four categories and each category was assigned a number. 
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Grade (1): no expression (-, 20=1); Grade (2): individual 
positive cells expressed in diseased area (+, 21=2); Grade (3): 
a few positive cells gathered together and expressed in the 
diseased area (++, 22=4) and Grade (4): wide spread of  
positive cells (+++, 23=8). Result is expressed in numbers 
according to different categories.
Expression of  PCNA was determined using a double 
blind method. For each section, 5 random fields at high 
resolution were chosen and positive cells were recorded by 
two analysts. Result is expressed as the mean positive cells 
recorded by the two analysts.  
Statistical analysis
Comparison of  the degree of  liver fibrosis between 
samples was performed by WILCOXON method. Other 
data were analyzed by SPSS11.0 software and reported 
as mean + standard deviation using one-way ANOVA. 
Student’s t-test was used for comparison between groups. 
P values of  0.05 or less are considered statistically 
significant.
RESULTS
WeiJia is an SFDA-approved Category-I new drug for the 
treatment of  severe hepatitis. WeJia showed an overall effi-
cacy of  88.9% in relieving symptoms and improving physi-
cal conditions of  chronic hepatitis patients in a treatment 
period of  six weeks in previous clinical study. Studies also 
showed that WeiJia can act as a therapeutic agent in the 
treatment of  cirrhosis[13, 14]. As progressive hepatic fibrosis 
would lead to cirrhosis, it is likely that WeiJia might also 
play a role in the treatment of  hepatic fibrosis. Thus the 
effect of  WeiJia on liver fibrosis was investigated through 
an animal model in this study. 
Rats were induced with CCl4 followed by the treatment 
with WeiJia. Animals without CCl4 induction or without 
WeiJia treatment were used as control for comparison. The 
effect of  CCl4 and WeiJia on rat liver fibrosis was deter-
mined through histological examination and serological 
markers test.
Biochemical tests of fibrosis
Serum levels of  biochemical markers were determined to 
evaluate the severity of  fibrosis. Levels of  extracellular ma-
trix constituents HA and CIV were measured which wer 
expected to increase as a result of  remodelling and recur-
rent scarring in liver fibrogenesis. HA has correlation with 
stage 3 and 4 fibrogenesis. Together with CIV and other 
markers, differentiation of  stage 1 and 2 fibrosis from 
stage 3 and 4 fibrosis can be obtained[18, 19]. HA and CIV 
serum levels for different treatment groups are shown in 
Table 1. Significant elevation of  serum HA and CIV levels 
were observed upon CCl4 induction (P < 0.001 vs Group 
A). Their levels were significantly reduced upon treatment 
with WeiJia (P < 0.005 vs Group B). Though there was still 
significant difference between the levels of  Group C and 
Group A rats at the fifth week, there was no apparent dif-
ference for CIV level at the eighth week between the two 
groups, indicating prolonged treatment with WeiJia could 
alleviate the severity of  fibrosis. Decrease of  the CIV and 
HA levels were observed for Group B rats at the 8th wk 
when compared to their level at the 5th wk indicating some 
recovery processes took place. However, such recovery 
processes were not potent enough to revert or alleviate the 
severity of  fibrosis as their enzyme levels were still signifi-
cantly higher than that of  Group A rats. 
Histopathological study
The great elevation of  HA and CIV levels upon CCl4 
induction indicated the successful generation of  liver fi-
brosis animal model. The result was further confirmed by 
histopathology study. HE staining for sections of  normal 
control group (Group A) showed structural integrity with-
out necrosis, inflammation or fibrosis development. VG 
staining for collagen was negative too. However, CCl4 in-
duced liver injury control group (Group B) showed signif-
icant fibrosis (P < 0.01) with the loss of  structural integ-
rity and formation of  nodules that lacked a central vein. 
Steatosis and ballooning degeneration (P < 0.01) were ob-
served on the fifth week whereas increased collagen fibres 
and complete fibrous septa were observed on the eighth 
week. Nevertheless, CCl4 induction with WeiJia treatment 
group (Group C) showed that WeiJia could significantly 
alleviate CCl4 induced alterations as seen in Group B rats. 
No obvious changes for fibrosis were observed on the 
fifth week (P > 0.05). However, the condition for balloon-
ing degeneration and steatosis were significantly relieved 
at this stage (P < 0.05). After prolonged treatment, a sig-
nificant reduction in inflammation, steatosis (P < 0.05), 
necrosis, fibrosis (P < 0.01) and collagen fibres (P < 0.05) 
were observed on the eighth week. Representative HE 
stained images of  sample on the eighth week are shown 
in Figure 1. There was no apparent difference between 
male and female rats. The degree of  fibrosis, ballooning 
degeneration and steatosis and collagen expression are 
summarized in Table 2, Table 3 and Table 4. 
Group  5th wk                     8th wk
HA µg/L CIV µg/L HA µg/L CIV µg/L
A   43 ± 19   19 ± 10   37 ± 17   46 ± 16
Bb 324 ± 92 206 ± 70 130 ± 52 136 ± 28
Ca   66 ± 20c   74 ± 19c   58 ± 22c   57 ± 211
Table 1 Liver fibrosis serum markers test for rats in different 
treatment group
n = 7 for each group, aP<0.005 vs Group B, b  < 0.001 vs Group A, cP < 0.05 vs 
Group A, 1P > 0.1 vs Group A.
Group 5th wk                                      8th wk
F0 F1 F2 F3 F4 F0 F1 F2 F3 F4
A 7  7
Bb 3 4 1 6
Ca,d 5 2 3 3 1
Table 2   Degree of fibrosis for rats in different treatment 
group
n = 7 for each group, aP > 0.05 vs Group B at fifth week, bP < 0.01 vs Group A, 
dP < 0.01 vs Group B at eighth week.
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Liver function test
The effect of  CCl4 on liver and the role of  WeiJia in 
treating liver fibrosis were also determined through liver 
function test. Serum levels of  ALT, AST and γ-GT were 
measured and compared with control groups as shown in 
Table 5. 
Significant increase in serum levels of  ALT, AST and 
γ-GT upon CCl4 induction were observed (P<0.005 Group 
B vs Group A). A significant decrease in the levels of  ALT 
and AST were observed after WeiJia treatment (P<0.05 
Group C vs Group B). However, the decrease was not 
significant for γ-GT (P > 0.1 Group C vs Group B). This 
indicates that there was no strong correlation between the 
degrees of  fibrosis and γ-GT as γ-GT is an indicator for 
primary or metastatic malignancy involving liver[20]. 
It has been known that ALT and AST are useful serum 
markers for inflammation and necrosis of  the liver. ALT is 
especially useful in acute and cholestatic diseases whereas 
AST is more sensitive in chronic and infiltrative lesion of  
the liver. Though the levels of  these enzymes decreased 
after WeiJia treatment, they were still significantly different 
when compared to Group A (P < 0.05), except the levels 
of  ALT and γ-GT at the fifth week. Studies have indicated 
that the ratio rather than the absolute values of  the two en-
zymes provides high specificity in monitoring fibrosis[21-23]. 
By comparing the ratio of  the two enzymes, there was no 
significant difference between rats treated with WeiJia and 
that from Group A. The results indicate that WeiJia could 
alleviate the adverse effect on liver function caused by liver 
injury. 
Immunohistochemical study
As WeiJia treatment could alleviate the effects caused by 
CCl4 induction, it is important to understand how WeiJia 
mediates its effect. It was suggested that the proliferative 
rate of  regenerating hepatocytes may be an important 
pathogenetic factor in chronic liver disease[24]. Recent stud-
ies have also shown that HSC are the primary cell type in 
mediating fibrogenesis[7-9]. Thus the expression of  PCNA 
and α-SMA were determined to evaluate the cell prolifera-
tion and HSC activation in liver injury respectively. Results 
are summarized in Table 6. 
Figure 1 Effect of different treatments on rat liver fibrosis induced by CCl4 (HE 
staining, ×100). A:  Normal control Group A rats, treated with vehicle for eight 
weeks; B: CCl4 induced control Group B rats, treated with CCl4 for eight weeks; C: 
CCl4 induced and WeiJia treatment Group C rats, treated with CCl4 for two weeks 




Group   5th wk                            8th wk
0 1 2 3 0 1 2 3
A 7 7
Bb 3 4 1 2 4
Ca 1 6 4 3
Table 3 Ballooning degeneration and steatosis for rats in 
different treatment group
n = 7 for each group, aP < 0.05 vs Group B, bP < 0.01 vs Group A.
Group 5th wk 8th wk
A 0 0
B b 5.2 ± 1.6 7.3 ± 1.6 
C 3.8 ± 0.9a 4.7 ± 1.0c
n = 7 for each group, aP > 0.05 vs Group B, bP < 0.01 vs Group A, cP < 0.05 vs 
Group B.
Table 4 Percentage collagen content for rats in different 
treatment groups
Group    5th wk                                    8th wk
ALT U/L AST U/L γ-GT U/L ALT U/L AST U/L γ-GT U/L
A   34 ± 12   99 ± 12  13 ± 7   32 ± 9 100 ± 19 15 ± 12
Ba 135 ± 24 158 ± 19 45 ± 23 133 ± 34 166 ± 28 74 ± 36
C   43 ± 12b,e 118 ± 10b,f 28 ± 19d,e   47 ± 10b,g 139 ± 13c,f 52 ± 21d,f 
Table 5 Liver function tests for rats in different treatment group
n = 7 for each group, aP < 0.005 vs Group A, bP < 0.001 vs Group B, cP < 0.05 
vs Group B, dP > 0.1 vs Group B, eP > 0.05 vs Group A, fP < 0.01 vs Group A, 
g P < 0.05 vs Group A.
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Normal hepatocytes are generally quiescent and repli-
cate in a limited and regulated manner[25-27]. High prolifera-
tive rates were reported in hepatocellular carcinoma, cir-
rhosis and acute hepatic failure[28-32]. Nevertheless, recent 
evidences showed that the replicative activity of  hepato-
cytes diminishes in advanced cirrhosis in humans and in 
chronic liver injury in mouse, reaching a state of  replicative 
senescence[33-35]. 
Only limited expression of  PCNA was found in nor-
mal control Group A whereas increased PCNA expression 
was observed upon CCl4 induction in active hepatocytes 
nuclei. Significant difference was found at the fifth week 
(P < 0.05, Group B vs Group A). However, expression of  
PCNA in Group B at the eighth week was not significantly 
different from that of  Group A. PCNA expression in-
creased further with WeiJia treatment (P < 0.05 Group C vs 
Groups A and B). 
In normal liver, HSCs are nonparenchymal quiescent 
cells for vitamin A storage. In pathological conditions as 
in liver fibrosis, HSCs lose retinoids and synthesize a large 
amount of  extracellular matrix components including col-
lagen, proteoglycan and adhesive glycoproteins. Morpholo-
gy of  these cells also changes from the star-shaped stellate 
cells to that of  fibroblasts or myofibroblasts[36]. α-SMA is a 
good indicator for HSC activation. 
Only limited α-SMA expression was observed in nor-
mal control group A. Upon CCl4 induction, increased 
amount of  α -SMA expression by activated HSC was ob-
served (P < 0.01 Group B vs Group A). The expression was 
reduced with WeiJia treatment. However, significant reduc-
tion was only observed at the eighth week (P < 0.05 Group 
C vs Group B). Though WeiJia could reduce α -SMA ex-
pression, its level was still significantly different from that 
of  Group A (P < 0.05 Group C vs Group A). The results 
indicated that WeiJia could mediate the alleviation of  CCl4 
induced injury through the proliferation of  regenerating 
hepatocytes and the reduction of  stellate cell activity. 
DISCUSSION
WeiJia is an effective therapeutic agent for severe hepatitis. 
However, its action mechanism is not clear. WeiJia was 
also shown to be effective in cirrhosis treatment. Thus we 
hypothesize that it may also play a role in fibrosis treat-
ment. In this study, its effect on liver fibrosis was evaluated 
through CCl4 induced liver injury animal model. This study 
also provides some information for understanding the 
mechanism of  WeiJia. 
It was found that treatment of  WeiJia could relieve 
CCl4 induced liver necrosis, ballooning degeneration, st-
eatosis and inflammation. The effect was significant at an 
early stage of  treatment at the fifth week. An improved 
liver function was also observed at this stage of  treatment. 
The results suggest that WeiJia protects liver cells from 
damage induced by CCl4 and the therapeutic effects of  
WeiJia on severe hepatitis might be related to the protec-
tive effect of  this medication. 
Upon liver injury, the body will attempt to repair the 
damage through increasing the expression of  hepatocyte 
growth factor (HGF), transforming growth factor beta 
(TGF-β) and other cytokines to enhance hepatocytes pro-
liferation and initiate tissue repairing process. Replicative 
activity of  hepatocytes diminishes in advanced cirrhosis in 
humans and in chronic liver injury in mouse [33-35]. PCNA 
expression in Group B was the response of  hepatocyte to 
liver damage. The level of  PCNA expression in Group C 
was significantly higher than that in Group B suggesting 
that liver cells of  rats in Group C have stronger replicative 
activity. The increase in PCNA expression in WeiJia treated 
rats with CCl4 induced liver damage demonstrated that 
WeiJia has protective effect on liver cells. 
Uncontrollable remodelling and regeneration would 
lead to the development of  fibrosis due to excessive depo-
sition of  extracellular matrix. The data from this inves-
tigation also showed that WeiJia was effective in fibrosis 
treatment. In addition to inflammation and necrosis, CCl4 
induction also resulted in collagen deposition and liver 
fibrosis as observed through histopathologic examination. 
Treatment with WeiJia reduced ballooning degeneration, 
steatosis and accumulation of  collagen. The effect was sig-
nificant at an early stage of  treatment at the fifth week. An 
improved liver function was also observed at this stage of  
treatment with the increase in PCNA expression. Signifi-
cant reduction of  fibrosis was only observed after a longer 
period of  treatment at the eighth week. Nevertheless, the 
results indicate that early treatment with WeiJia might 
prevent the progression of  liver injury to fibrosis through 
increased liver regeneration and reduced liver necrosis. 
It is believed that HSC activation is a critical step in 
hepatic fibrosis. Levels of  serological markers (HA, CIV) 
and α-SMA expression clearly indicated that HSC was acti-
vated by CCl4 induced liver injury. WeiJia treatment led to a 
significant reduction of  theses proteins, indicating that the 
mechanism of  WeiJia in reducing hepatic fibrosis may be 
through the inactivation of  HSC.
In conclusion, WeiJia is shown to be an effective thera-
peutic agent that could alleviate liver fibrosis through the 
stimulation of  liver regeneration and inhibition of  HSC 
activation.
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